Payment overview · 2025
General Payments
$688.38
27 reported records · 12 companies
Healthcare provider profile · identity verified
Richard Fullerton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1225133945
Verified facts
What the public records show
CMS Open Payments records show Richard Fullerton, MD received $688.38 in general payments during 2025 across 27 reported records.
Inspire Medical Systems, Inc. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $126.18 | 18.3% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $123.95 | 18.0% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $104.78 | 15.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $92.84 | 13.5% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $63.51 | 9.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $43.49 | 6.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $42.54 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.35 | 3.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.78 | 2.6% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $17.06 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.99 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.91 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $688.38 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $126.18 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $123.95 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $104.78 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $104.78 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $92.84 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.50 | 3 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $43.49 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $42.54 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.35 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 86 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
86 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
194 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 684 | 190 |
| Amlodipine Besylate | Amlodipine Besylate | 593 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 531 | 138 |
| Gabapentin | Gabapentin | 393 | 124 |
| Trazodone Hcl | Trazodone Hcl | 347 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 312 | 82 |
| Lisinopril | Lisinopril | 290 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 285 | 74 |
| Losartan Potassium | Losartan Potassium | 272 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 66 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 215 | 62 |
| Tramadol Hcl | Tramadol Hcl | 210 | 65 |
| Omeprazole | Omeprazole | 208 | 65 |
| Simvastatin | Simvastatin | 204 | 60 |
| Alprazolam | Alprazolam | 202 | 53 |
| Eliquis | Apixaban | 194 | 37 |
| Sertraline Hcl | Sertraline Hcl | 191 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 66 |
| Zolpidem Tartrate | Zolpidem Tartrate | 178 | 46 |
| Montelukast Sodium | Montelukast Sodium | 175 | 71 |
| Metformin Hcl | Metformin Hcl | 172 | 59 |
| Allopurinol | Allopurinol | 148 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 136 | 27 |
| Furosemide | Furosemide | 131 | 52 |
| Clonazepam | Clonazepam | 125 | 26 |
| Bupropion Xl | Bupropion Hcl | 120 | 39 |
| Meloxicam | Meloxicam | 119 | 39 |
| Synthroid | Levothyroxine Sodium | 110 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 110 | 34 |
| Methylprednisolone | Methylprednisolone | 104 | 90 |
| Diclofenac Sodium | Diclofenac Sodium | 100 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 96 | 79 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 89 | 36 |
| Potassium Chloride | Potassium Chloride | 88 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 31 |
| Carvedilol | Carvedilol | 86 | 20 |
| Ozempic | Semaglutide | 86 | 15 |
| Valacyclovir | Valacyclovir Hcl | 83 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 80 | 24 |
| Ezetimibe | Ezetimibe | 77 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 30 |
| Azithromycin | Azithromycin | 75 | 66 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 23 |
| Metformin Hcl Er | Metformin Hcl | 72 | 22 |
| Atenolol | Atenolol | 71 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 71 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 20 |
| Finasteride | Finasteride | 65 | 20 |
| Prednisone | Prednisone | 63 | 39 |
| Linzess | Linaclotide | 60 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 16 |
| Lorazepam | Lorazepam | 54 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 20 |
| Meclizine Hcl | Meclizine Hcl | 51 | 25 |
| Alendronate Sodium | Alendronate Sodium | 50 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 34 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 47 | 12 |
| Famotidine | Famotidine | 47 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 16 |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Glipizide | Glipizide | 46 | 13 |
| Azelastine Hcl | Azelastine Hcl | 45 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Glimepiride | Glimepiride | 43 | 12 |
| Nifedipine Er | Nifedipine | 42 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 37 |
| Valsartan | Valsartan | 41 | 12 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Diazepam | Diazepam | 39 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 33 |
| Verapamil Er | Verapamil Hcl | 36 | 11 |
| Estradiol | Estradiol | 35 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | 11 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 13 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Irbesartan | Irbesartan | 33 | 11 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 23 |
| Ibuprofen | Ibuprofen | 30 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Klor-Con M20 | Potassium Chloride | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Torsemide | Torsemide | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Travoprost | Travoprost | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $688.38 · 27 records | Inspire Medical Systems, Inc. | AREXVY, EVENITY, General - Pain Management, INSPIRE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, SHINGRIX, TZIELD, UBRELVY, Xhance, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error